Search results for "Allergic asthma"

showing 6 items of 26 documents

Free Serum IgE In Patients With Severe Allergic Asthma Treated With Omalizumab

2010

business.industryImmunologyMedicineAllergic asthmaIn patientOmalizumabbusinessSerum igemedicine.drugD101. DIAGNOSIS AND TREATMENT OF ASTHMA
researchProduct

Reduction Of Pulmonary Inflammation Through HIV-1 Envelope Protein GP120 In A Humanized Mouse Model Of Allergic Asthma Depends On Regulatory T Cells

2011

business.industryPulmonary inflammationHumanized mouseImmunologyMedicineAllergic asthmabusinessHiv 1 envelopeB32. ALLERGIC INFLAMMATION: MECHANISMS
researchProduct

Allergic Asthma and Aging

2012

Gabriele Di Lorenzo1, Danilo Di Bona2,3, Simona La Piana2, Vito Ditta4 and Maria Stefania Leto-Barone1 1Dipartimento di Medicina Interna e Specialistica (DIMIS), Universita degli Studi di Palermo 2Dipartimento di Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita degli Studi di Palermo 3Unita Operativa di Immunoematologia e Medicina Trasfusionale, Azienda Ospedaliera, Universitaria Policlinico di Palermo 4Centro Trasfusionale ASPPalermo. P.O. San Raffaele G. Giglio Cefalu, Palermo Italia

immune system diseasesmedia_common.quotation_subjectAllergic asthmaArtHumanitiesrespiratory tract diseasesmedia_common
researchProduct

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentratio…

2015

Background: OMA is an effective treatment option in SAA. However, little data are available on the long-term-efficacy oft the drug. Objective: To determine the long-term efficacy of OMA in respect to clinical parameters and IgE serum levels. Methods: This was a retrospective, open-label, uncontrolled, multi-center observational study according to the definition of non-interventional studies. 22 non-smoking patients (10 m, 12 f; mean age 47,9 yrs) with SAA were enrolled. Pat were treated with OMA up to for 4 years and total serum IgE levels were assessed at initiation of therapy, after 2-6 ms and 3-5 yrs. Data were recorded on standardized CRFs by the treating physician. Results: The average…

medicine.medical_specialtybiologybusiness.industryAllergic asthmaAtopic dermatitisOmalizumabImmunoglobulin Emedicine.diseaseGastroenterologyTreatment periodSerum igeFood allergyInternal medicineConcomitantImmunologybiology.proteinmedicinebusinessmedicine.drug5.3 Allergy and Immunology
researchProduct

High training volume is associated with increased prevalence of non-allergic asthma in competitive cross-country skiers.

2022

BackgroundCross-country skiers have a high prevalence of asthma, but its phenotypes and association with success in competitions are not known.ObjectiveTo investigate, by means of a postal survey, the relative proportions of allergic and non-allergic asthma in competitive cross-country skiers compared with the general population, to study how performance level and training volume are related to asthma and its type and to assess the possible risk factors for allergic and non-allergic asthma in competitive skiers.MethodsAll Finnish cross-country skiers enrolled in the largest national competitions in winter 2019 (n=1282), and a random sample (n=1754) of the general population of the same age …

sairastavuusprevalencePhysical Therapy Sports Therapy and Rehabilitation3121 Internal medicinerespiratory tract diseaseshiihtäjät3141 Health care scienceimmune system diseasesnon-allergic asthmaastmaharjoitteluOrthopedics and Sports Medicinecross-country skiershengityselinten taudit315 Sport and fitness scienceshuman activitieshigh training volumehuippu-urheilijatBMJ open sportexercise medicine
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct